期刊文献+

脂肪酸酰化修饰胰岛素的纯化 被引量:1

Purification of Acylated Insulin by Polymer Resin
原文传递
导出
摘要 目的:脂肪酸酰化修饰的胰岛素类似物是常见的获得长效胰岛素的手段,但因其反应位点的偏差易产生多种传统纯化工艺较难以分离的杂质。本文探索以聚苯乙烯类有机聚合物填料为固定相纯化脂肪酸酰化修饰的胰岛素方法。方法:经过填料对比,有机溶剂浓度和pH选择后,再经过一系列正交试验优化,HPLC方法检验纯度和含量,质谱分析定性终产品,从而确定最佳条件。结果:经过对不同厂家不同型号的聚苯乙烯类有机聚合物填料的比较,填料选定采用纳微Uni Ps 30-300为最佳,其目的蛋白吸附量比为6.32 mg/ml,洗脱率为95.27%。在一系列的梯度实验中证实采用30-50%异丙醇浓度最佳。之后的pH对比得出,pH在4.0以下才能分离得到纯度在95%以上的产品。在以上一系列的单因素实验基础上,最后经过正交实验优化证实最佳的洗脱方案为采用A相为含25 mM硫酸铵的0.1 M磷酸盐缓冲液,pH 3.0;B相为异丙醇流动相,洗脱梯度为30-50%B的10 CV洗脱,流速60 cm/h。放大验证可以得到纯度大于97.5%,回收率70%以上的结果。结论:此方法具有分离效果好,成本低,易于放大的优点。 Objective: Modification of insulin with Fattyacid is the most common way to obtain Long-acting Insulin. But some im- purities would be generated during the acylation of insulin, which are hard to separated by traditional methods of purification. The paper aimed to setup an optimal method for purifying acylated insulin by polymer resins. Method: One-factor experiments related to the facts: resins, pH and solvents, and Orthogonal experiment were adopted. The concentration and purity of acylated insulin was measured by HPLC and MALDI-TOF MS. Result: In the experiment related to the selection of resins, Uni Ps 30-300 showed a higher adsorbtion rate of 6.32 mg/mL, and a higher recovery rate of 95.27 %. The experiments also showed that the optimum solvent for elution should be 30-50 % isopropyl alcohol, and pH value should be 4.0 or lower to remove the impurities. And finally the Orthogonal experiment's result showed the best protocol as follows: Buffer system consisted of an A-Buffer 0.1 M Phosphate salt buffer, 0.025 M (NH4)2SO4, pH 3.0 and Buffer B consisting of isopropyl alcohol. The crude product was eluted with a linear gradient from 30 % B to 50 % B in 10 CV, and the linear velocity was 60 em/h. The final product's purity can reach up to 97.5 %, and recovery rate was more than 70%. Conclusion: This technology is considered simple, cheap and suitable for industrialization.
出处 《现代生物医学进展》 CAS 2013年第24期4785-4790,共6页 Progress in Modern Biomedicine
基金 广东省华南理工大学博士后流动站研究课题:新型长效胰岛素创新项目 财政部蛋白类生物药和疫苗发展专项
关键词 酰化胰岛素 聚合物填料 纯度 回收率 Acylated insulin Polymer resin Purity Recovery rate
  • 相关文献

参考文献19

  • 1陆菊明.糖尿病研究现状及展望[J].解放军医学杂志,2010,35(7):777-780. 被引量:41
  • 2贺星,田红,徐颂,李艳凤,陈常青.糖尿病治疗药物的研究进展[J].现代药物与临床,2009,24(3):129-133. 被引量:41
  • 3Scemons D. Are you up-to-date on diabetes medications [J]. Nursing, 2007, 37 (7): 49-50.
  • 4Mazzola N. Review of current and emerging therapies in type 2 dia- betes mellitus [J]. Am J Manag Care, 2012 Jan; 18(1 Suppl): S17-26.
  • 5母义明,陈康.成人2型糖尿病胰岛素临床应用中国专家共识解读[J].中国医学前沿杂志(电子版),2012,4(3):52-53. 被引量:5
  • 6Waugb N, Cummins E, Royle P, etc. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation [J]. Health Technol Assess, 2010 Jul; 14(36): 241-248.
  • 7Berenson DF, Weiss AR, Wan ZL, et al. Insulin analogs for the treat- ment of diabetes mellitus: therapeutic applications of protein engi- neering [J]. Annals OF the New York Academy of Sciences, 2011, 12 (1243): 40-54.
  • 8Pandyarajan V, Weiss MA. Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus [J]. Current Diabetes Reports, 2012, 12(6): 697-704.
  • 9Keating GM. Insulin detemir: a review of its use in the management of diabetes mellitus [J]. Drugs, 2012, 72(17): 2255-2287.
  • 10Havelund S, Plum A. The Mechanism of Protraction of Insulin De- temir, a Long-Acting, Acylated Analog of Human Insulin [J]. Phar- maceutical Research, 2004 Aug; 21(8): 1498-1504.

二级参考文献46

  • 1张莉静,卢曦.基于PPAR抗糖尿病药物的研究进展[J].国外医学(药学分册),2004,31(5):287-291. 被引量:21
  • 2孙忠实.口服降糖新药——那格列奈[J].实用糖尿病杂志,2006,2(4):53-54. 被引量:4
  • 3赵惠珠.胰岛素类似物的临床应用[J].中国医学文摘(内科学),2006,27(4):363-364. 被引量:4
  • 4王璐,邸阜生.肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用[J].医学综述,2007,13(1):25-27. 被引量:6
  • 5Wild S, Roglic G, Green A, et al. Global prevalence of diabetes [J]. Diabetes Care, 2004, 27(5): 1047-1053.
  • 6Bando K, Yamada Y. Glimepiride (Amary1): a review pharmacological and clinical profile [J]. Nippon Yakufigaku Zas, 2001, 118: 59-67.
  • 7Willson T M, Brown P J, Sternbach D D, et al. The PPARs: From orphan receptors to drug discovery [J]. J Med Chem, 2000, 43(4): 527-550.
  • 8Day C. Thiazolidinediones: a new class of antidiabctic drugs [J]. Diabet Med, 1999, 16(3): 179-192.
  • 9Cox S L. Muraglitazar: An agent for the treatment of type 2 diabetes and associated dyslipidemia [J]. Drugs Today, 2005, 41(9): 579-587.
  • 10Shibata T, Matsui K, Nagao K, et al. Pharmacological pro files of a novel oral antidiabetic agent JTT-501, an isoxazo lidinedione derivative [J]. Eur J Pharmacol, 1999, 364 (2/ 3): 211-219.

共引文献84

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部